z-logo
open-access-imgOpen Access
Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)
Author(s) -
Imamura Hiroshi,
Matsuyama Jin,
Nishikawa Kazuhiro,
Endo Shunji,
Kawase Tomono,
Kimura Yutaka,
Fukui Junichi,
Kawada Junji,
Kurokawa Yukinori,
Fujitani Kazumasa,
Sakai Daisuke,
Kawakami Hisato,
Tsujinaka Toshimasa,
Shimokawa Toshio,
Matsubara Yoshihiro,
Satoh Taroh,
Furukawa Hiroshi
Publication year - 2021
Publication title -
annals of gastroenterological surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.308
H-Index - 15
ISSN - 2475-0328
DOI - 10.1002/ags3.12487
Subject(s) - medicine , gastrectomy , clinical endpoint , chemotherapy , gastroenterology , adjuvant , cancer , adverse effect , neutropenia , surgery , clinical trial
Aim Post‐surgical weight loss influences chemotherapy compliance and may be a risk factor for survival. Intake of an oral elemental nutritional supplement (OENS) can reduce weight loss after gastric cancer (GC) surgery. We assessed whether therapy completion levels would increase in patients receiving postoperative adjuvant chemotherapy in combination with an OENS. Methods This was a multicenter, open‐label, single‐arm, phase II study in GC patients who underwent curative total or distal gastrectomy (TG/DG) and received adjuvant S‐1 chemotherapy. The primary endpoint was the S‐1 completion rate for 1 year with a relative performance (RP) value of ≥70%; secondary endpoints included factors affecting the completion rate of S‐1, RP value after eight S‐1 courses, S‐1 and OENS persistence rates, nutritional index, OENS compliance, and safety. Results In 71 efficacy‐evaluable patients, the S‐1 completion rate was 69.0% (TG, 68.0%; DG, 69.6%) and the RP value was 87.5 (TG, 89.1; DG, 87.5). Over eight treatment courses, median persistence rates were 89.0% for S‐1 and 93.8% for the OENS. The mean OENS compliance was 81.8% at the fourth S‐1 course and 52.9% at the eighth course. The incidence of Grade 3 or 4 adverse events was 27.2%, most commonly neutropenia (12.3%). Conclusions The completion rate of S‐1 for 1 year in patients who could take the OENS exceeded the pre‐defined threshold level. Randomized controlled trials are warranted to confirm the role of OENS in adjuvant chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here